Prime Medicine Q2 FY26 net loss narrows to $42.1 million

Reuters2026/08/06 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Prime Medicine posted a net loss of USD 42.1 million for Q2 2026, narrowing from USD 52.6 million a year earlier.
R&D expense fell 19.32% to USD 33.4 million, due to lower personnel costs following a May 2025 workforce reduction and facility savings.
G&A costs dropped 16.03% to USD 11 million on lower personnel costs, reduced stock-based compensation, and lower corporate legal fees.
Cash, cash equivalents, investments, and restricted cash totaled USD 108.8 million as of June 30, 2026, down from USD 191.4 million at Dec. 31, 2025.
FDA cleared a US IND for PM577a in Wilson disease; an IND and/or CTA for PM647 is expected in Q3 2026, with both programs’ initial data slated for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053878), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Prime Medicine Q2 FY26 net loss narrows to $42.1 million

You may also like

Crypto prices